# HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

> **NCT06333561** · — · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 300 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Lenvatinib
- PD-1 Inhibitor
- Hepatic Arterial Infusion Chemotherapy

## Interventions

- **PROCEDURE:** Hepatic arterial infusion chemotherapy
- **DRUG:** Lenvatinib
- **DRUG:** Tislelizumab
- **DRUG:** Toripalimab
- **DRUG:** Sintilimab
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT06333561
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06333561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06333561, "HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06333561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*